# A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

> **NCT00099177** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 96 (actual)

## Conditions studied

- Pain
- Bone Neoplasm
- Neoplasm Metastasis

## Interventions

- **DRUG:** ibandronate [Bondronat]
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00099177
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2017-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099177, "A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00099177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*